Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis
|
|
- ようた やぶき
- 5 years ago
- Views:
Transcription
1 Staphylococcus aureus S. aureus (MRSA) vancomycin (VCM), arbekacin (ABK) Streptococcus pneumoniae cefuzonam (CZON), cefpirome (CPR) S. pneumoniae Enterococcus faecalis ampicillin (ABPC), imipenem (IPM) Escherichia coli Klebsiella pneumoniae Haemophilus influenzae ciprofloxacin (CPFX) Pseudomonas aeruginosa Staphylococcus epidermidis Key words: susceptibility, g-lactam, methicillin-resistant S. aureus (MRSA), meca gene, S. epidermidis
2 Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organisms and antibacterial agents used MIC determination performed. ABPC: ampicillin, AMPC: amoxicillin, MPIPC: axacillin, DMPPC: methicillin, PCG: benzylpenicillin, PIPC: piperacillin, CEZ: cefazolin, CTM: cefotiam, CMZ: cefmetazole, CAZ: ceftazidime, CZON: cefuzonam, CPZ: cefoperazone, SBT/CPZ: sulbactum/ cefoperazone, CPR: cefpirome, CFS, cefsulodin, CFX: cefoxitin, LMOX: latamoxef, FMOX: flomoxef, CCL: cefaclor, CETB: ceftibuten, CFDN: cefdinir, IPM: imipenem, MEPM: meropenem, AZT: aztreoram, TOB: tobramycin, AMK: amikacin, ABK: arbekacin, OFLX: ofloxacin, CPFX: ciprofloxacin, LFLX: lomefloxacin, EM: erythromycin, CLDM: clindamycin, FOM: fosfomycin, TC: tetracycline, MINO: minocycline, CP: chloramphenicol, VCM: vancomycin, ST: sulfamethoxazole-trimethoprim, MTZ: metronidazole
3 S. epidemidis: S. epidemidis S. aureus: S. aureus S. aureus aureus (MRSA)13) S. pneumoniae: S. pneumoniae E. faecalis: Table 2. Susceptibility distribution of clinical isolates of MSSA (90 isolates) MSSA: methicillin-susceptible Staphylococcus aureus (MPIPC MIC: 3.13 Đg/ml) MPIPC: oxacillin, DMPPC: methicillin, CEZ: cefazolin, CTM: cefotiam, CMZ: cefmetazole, CZON: cefuzonam, FMOX: flomoxef CPR: cefpirome, CCL: cefaclor, CFDN: cefdinir, IPM: imipenem, MEPM: meropenam, TOB: tobramycin, ABK: arbekacin, OFLX:, ofloxacin, LFLX: lomefloxacin, EM: erythromycin, TC: tetracycline, MINO: minocycline, VCM: vancomycin, ST: sulfamethoxazole-trimethoprim, FOM: fosfomycin
4 VOL. 43 NO. 1 Table 3. Susceptibility distribution of clinical isolates of MRSA (125 isolates) MRSA: methicillin-resistant Staphylococcus aureus (MPIPC MIC: _0026g/ml) MPIPC: oxacillin, DMPPC: methicillin, CEZ: cefazolin, CTM: cefotiam, CMZ: cefmetazole, CZON: cefuzonam, FMOX: flomoxef, CPR: cefpirome, CCL: cefaclor, CFDN: cefdinir, IPM: imipenem, MEPM: meropenam, TOB: tobramycin, ABK: arbekacin, OFLX: ofloxacin, LFLX: lomefloxacin, EM: erythromycin, TC: tetracycline, MINO: minocycline, VCM: vancomycin, ST: sulfamethoxazole-trimethoprim, FOM: fosfomycin Table 4. Susceptibility distribution of clinical isolates of Staphylococcus epidermidis (139 isolates) MPIPC: oxacillin, DMPPC: methicillin, CEZ: cefazolin, CZON: cefuzonam, FMOX: flomoxef, CPR: cefpirome, CCL: cefaclor, CFDN: cefdinir, IPM: imipenem, MEPM: meropenam, TOB: tobramycin, OFLX: ofloxacin, CPFX: ciprofloxacin, LFLX: lomefloxacin, VCM: vancomycin
5 K. pneumoniae: P. mirabilis: Table 5. Susceptibility distribution of clinical isolates of Streptococcus pneumoniae (51 isolates) AMPC: amoxicillin, PCG: benzylpenicillin, CEZ: cefazolin, CTM: cefotiam, CMZ: cefmetazole, CAZ: ceftazidime, CZON: cefuzonam, FMOX: flomoxef, CPR: cefpirome, CCL: cefaclor, CFDN: cefdinir, IPM: imipenem, MEPM: meropenem, OFLX: ofloxacin, CPFX: ciprofloxacin, LFLX: lomefloxacin, EM: erythromycin, VCM: vancomycin Table 6. Susceptibility distribution of clinical isolates of Enterococcus faecalis (99 isolates) ABPC: ampicillin, SBT/CPZ: sulbactum/cefoperazone, FMOX: flomoxef, CPR: cefpirome, CCL: cefaclor, CFDN: cefdinir, IPM: imipenem, MEPM: meropenem, TOB: tobramycin, OFLX: ofloxacin, CPFX: ciprofloxacin, LFLX: lomefloxacin, VCM: vancomycin
6 VOL.43 NO.1 Table 7. Susceptibility distribution of clinical isolates of Escherichia coil (168 isolates) ABPC: ampicillin, AMPC: amoxicillin, CEZ: cefazolin, CTM: cefotiam, CMZ: cefmetazole, SBT/CPZ: sulbactum/cefoperazone, CAZ: ceftazidime, CZON: cefuzonam, LMOX: latamoxef, FMOX: flomoxef, CPR: cefpirome, CCL: cefaclor, CFDN: cefdinir, CETB: ceftibuten, IPM: imipenern, MEPM: meropenem, AZT: aztreonam, TOB: tobramycin, OFLX: ofloxacin, CPFX: ciprofloxacin, LFLX: lomefloxacin, MINO: minocycline, FOM: fosfomycin P. vulgaris: H. influenzae: C. freundii: E. cloacae: M. catarrhalis: S. marcescens: N. gonorrhoeae: P. aeruginosa:
7 Table 8. Susceptibility distribution of clinical isolates of Klebsiella pneumoniae (90 isolates) ABPC: ampicillin, AMPC: amoxicillin, CEZ: cefazolin, CTM: cefotiam, CMZ: cefmetazole, SBT/CPZ: sulbactum/cefoperazone, CAZ: ceftazidime, LMOX: latamoxef, FMOX: flomoxef, CPR: cefpirome, CCL: cefaclor, CFDN: cefdinir, CETB: ceftibuten, IPM: imipenem, MEPM: meropenem, AZT: aztreonam, TOB: tobramycin, OFLX: ofloxacin, CPFX: ciprofloxacin, LFLX: lomefloxacin, MINO: minocycline B. fragilis: S. aureus S. epidermidis S. andermidis
8 VOL.43 NO. 1 Table 9. Susceptibility distribution of clinical isolates of Proteus mirabilis (56 isolates) ABPC: ampicillin, AMPC: amoxicillin, CEZ: cefazolin, CTM: cefotiam, CMZ: cefmetazole, SBT/CPZ: sulbactum/cefoperazone, CAZ: ceftazidime, CZON: cefuzonam, LMOX: latamoxef, FMOX: flomoxef, CPR: cefpirome, CCL: cefaclor, CFDN: cefdinir, CETB: ceftibuten, IPM: imipenem, MEPM: meropenem, AZT: aztreonam, TOB: tobramycin, OFLX: ofloxacin, CPFX: ciprofloxacin, LFLX: lomefloxacin, FOM: fosfomycin Table 10. Susceptibility distribution of clinical isolates of Proteus vulgaris (49 isolates) SBT/CPZ: sulbactum/cefoperazone, CAZ: ceftazidime, CZON: cefuzonam, LMOX: latamoxef, FMOX: flomoxef, CPR: cefpirome, CFDN: cefdinir, CETB: ceftibuten, 1PM: imipenem, MEPM: meropenem, AZT: aztreonam, TOB: tobramycin, AMK: amikacin, OFLX: ofloxacin, CPFX: ciprofloxacin, LFLX: lomefloxacin, FOM: fosfomycin
9 Table 11. Susceptibility distribution of clinical isolates of Citrobacter freundii (58 isolates) SBT/CPZ: sulbactum/cefoperazone, CAZ: ceftazidime, CZON: cefuzonam, LMOX: latamoxef, FMOX: flomoxef, CPR: cefpirome, CCL: cefaclor, CFDN: cefdinir, CETB: ceftibuten, IPM: imipenem, MEPM: meropenem, AZT: aztreonam, TOB: tobramycin, AMK: amikacin, OFLX: ofloxacin, CPFX: ciprofloxacin, LFLX: lomefloxacin, MINO: minocycline, Table 12. Susceptibility distribution of clinical isolates of Enterobacter cloacae (93 isolates) CPZ: cefoperazone, SBT/CPZ: sulbactum/cefoperazone, CAZ: ceftazidime, CZON: cefuzonam, LMOX: latamoxef, FMOX: flomoxef, CPR: cefpirome, CETB: ceftibuten, IPM: imipenem, MEPM: meropenem, AZT: aztreonam, TOB: tobramycin, AMK: amikacin, OFLX: ofloxacin, CPFX: ciprofloxacin, LFLX: lomefloxacin, MINO: minocycline
10 Table 13. Susceptibility distribution of clinical isolates of Serratia marcescens (93 isolates) SBT/CPZ: sulbactum/cefoperazone, CAZ: ceftazidime, CZON: cefuzonam, LMOX: latamoxef, FMOX: flomoxef, CPR: cefpirome, CETB: ceftibuten, IPM: imipenem, MEPM: meropenem, AZT: aztreonam, AMK: amikacin, OFLX: ofloxacin, CPFX: ciprofloxacin, LFLX: lomefloxacin, FOM: fosfomycin Table 14. Susceptibility distribution of clinical isolates of Haemophilus influenzae (60 isolates) ABPC: ampicillin, AMPC: amoxicillin, SBT/CPZ: sulbactum/cefoperazone, CAZ: ceftazidime, CZON: cefuzonam, LMOX: latamoxef, FMOX: flomoxef, CPR: cefpirome, CCL: cefaclor, CFDN: cefdinir, CETB: ceftibuten, 1PM: imipenem, MEPM: meropenem, AZT: aztreonam, TOB: tobramycin, OFLX: ofloxacin, CPFX: ciprofloxacin, LFLX: lomefloxacin, EM: erythromycin, MINO: minocycline
11 Table 15. Susceptibility distribution of clinical isolates of Moraxella (B.) catarrhalis (38 isolates) SBT/CPZ: sulbactum/cefoperazone, CAZ: ceftazidime, CZON: cefuzonam, LMOX: latamoxef, FMOX: flomoxef, CPR: cefpirome, CCL: cefaclor, CFDN: cefdinir, CETB: ceftibuten, IPM: imipenem, MEPM: meropenem, TOB: tobramycin, OFLX: ofloxacin, CPFX: ciprofloxacin, LFLX: lomefloxacin, EM: erythromycin, MINO: minocycline Table 16. Susceptibility distribution of clinical isolates of Neisseria gonorrhoeae (23 isolates) ABPC: ampicillin, AMPC: amoxicillin, SBT/CPZ: sulbactum/cefoperazone, CAZ: ceftazidime, CZON: cefuzonam, LMOX: latamoxef, FMOX: flomoxef, CPR: cefpirome, CCL: cefaclor, CFDN: cefdinir, CETB: ceftibuten, IPM: imipenem, MEPM: meropenem, AZT: aztreonam, OFLX: ofloxacin, CPFX: ciproxacin, LFLX: lomefloxacin, EM: erythromycin, MINO: minocycline, TC: tetracycline
12 VOL.43 NO.1 Table 17. Susceptibility distribution of clinical isolates of Pseudomonas aeruginosa (103 isolates) PIPC: piperacillin, SBT/CPZ: sulbactum/cefoperazone, CAZ: ceftazidime, CFS: cefsulodin, LMOX: latamoxef, CPR: cefpirome, IPM: imipenem, MEPM: meropenem, AZT: aztreonam, TOB: tobramycin, AMK: amikacin, OFLX: ofloxacin, CPFX: ciprofloxacin, LFLX: lomefloxacin, FOM: fosfomycin Table 18. Susceptibility distribution of clinical isolates of Bacteroides fragilis (48 isolates) PIPC: piperacillin, CFS: cefsulodin, CMZ: cefmetazole, CAZ: ceftazidime, SBT/CPZ: sulbactum/cefoperazone, LMOX: latamoxef, FMOX: flomoxef, CPR: cefpirome, CETB: ceftibuten, IPM: imipenem, MEPM: meropenem, OFLX: ofloxacin, CPFX: ciprofloxacin, LFLX: lomefloxacin, CLPM: clindamycin, CP: chloramphenicol, MTZ: metronidazole S. epidermidis (MRSE) S. pneumoniae S. pneumoniae S. pneumoniae E. coli, K. pneumoniae, P. mirabilis
13 Table 19. Correlations between the MICs of oxacillin and those of methicillin and flomoxef in Staphylococcus aureus Oxacillin MIC 3.13ƒÊg/ml,2Oxacillin MIC 6.25ƒÊg/ml Table 20. Correlations between the presence of the meca gene in Staphylocoucus us epidermidis and susceptibility to Absence of the mec A gene, 2)Presence of the mec A gene C. freundii E. cloacae E. cloacae E. aerogenes P. aerugznosa S. marcescens B. fragilis S. pneumoniae, E. faecalis S. pneumoniae E. coli, K. pneumoniae E. coli, K. pneumoniae, H. influenzae umoniae, C. freundii, E. cloacae E. faecalis P. aeruginosa B. fragilis P. aeruginosa
14 VOL.43 NO.1 aureus S. aureus S. aureus 5) Hansman D, Bullen M M: A resistant pneumococcus. Lancet 2:264 `265, ) Jacobs M R, Koonrnhof H J, Robins-Broune R I, Miller G B, Witcomb M A, Isaacson M, Ward J I, Austrian R: Emergence of multiply resistant pneumococci. N. Engl. J. Med. 299: 735 `740, ) National Committee for Clinical Laboratory Standards.: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 2 nd ed. M 7-A 2 National Committee for Clinical Laboratory Standards., Villanova, Pa ) Payne D J: Metallo-P-lactamases a new therapeutic charange. J. Med. Microbiol. 39: 93 `99, 1993 S. epidermidis S. epidermidis Serratiamarcescens epidermidis 16) Suzuki E, Hiramatsu K, Yokota T: Survey of methycillin-resistant clinical strains of coagulase egative staphylococci for mec A gene distribution. Antimicrob. Agents Chemother. 36:429 `434, 1992
15 Surveillance of the susceptibility of clinical isolates of various bacterial species to antibacterial agents Shimaru Sasaki, Kaoru Nagano, Yoshiji Kimura, Yutaka Jinushi, Hiroshi Nagata, Kouichi Uotani and Isao Higashiyama Kanzakigawa Laboratories, Shionogi Research Laboratories, Shionogi and Co., Ltd., Futaba-cho, Toyanaka, Osaka 561, Japan We used agar-dilution MIC determinations to asses the activity of 39 antibacterial agents against various clinical isolates (16 species, 1,386 strains), most of which were isolated in 1992 at 18 facilities in Japan. We found that 58.1% of the strains of Staphylococcus aureus were methicillin-resistant S. aureus (MRSA) Vancomycin (VCM) and arbekacin (ABK) proved to have the highest antibacterial activity against these MRSA with an MIC90 of 0.78 and 1.56 ƒêg/ ml, respectively. Most of the fl-lactam antibiotics displayed high antibacterial activity against Streptococcus pneumoniae, especially cefuzonam (CZON), cefpirome (CPR) and the carbapenems, whose MICH was less than 0.39ƒÊg/ml. The incidence of penicillin-resistant S. pneumoniae was 37.0%. The agents which showed the highest antibacterial activity against Enterococcus faecalis were ampicillin (ABPC), imipenem (IPM) and VCM (MICK) 3.13,ig/ml). Most cephems, carbapenems and quinolones exhibited high antibacterial activity against Escherichia coli and Klebsiella pneumoniae with an MIC90 of less than 3.13ƒÊg/ml. Most cephems, carbapenems and quinolones also showed high antibacterial activity against Haemophilus influenzae, with that of ciprofloxacin (CPFX) being especially high with MICK, of pg/ml. ABPC-resistant H. influenzae accounted for 10.0% of the H. influenzae strains. Carbapenems displayed the highest antibacterial activity against Pseudomonas aeruginosa (MIC ƒêg/ml). Ceftazidime (CAZ) -resistant P. aeruginosa strains and IPM-resistant P. aeruginosa strains accounted for 29.1% and 8.7% of their groups, respectively, while quinolone-resistant strains represented %. Suitable antibiotics for detecting MRSA by agar-dilution MIC determination were oxacillin (MPIPC) and flomoxef (FMOX). meca-positive strains accounted for 73.4% of Staphylococcus epidermidis strains and the presence of the meca gene coincided with MPIPC susceptibility.
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis, E.coil,Klebsiella pneumoniae,klebsiella oxytoca,proteus
More information日本化学療法学会雑誌第64巻第4号
β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.
More information03-b-„FŒ{›xŒ¾-4.02
518( 30 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 1. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 519( 31 ) 9 5 2003 8 2004 7 14 565 701 258 (36.8%) 443 (63.2%) Staphylococcus aureus
More information日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
More informationVOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus
MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,
More informationR06_01
Staphylococcus aureus (MSSA) PCG (N=118,334) 57,369 (48.5%) 判定不能 :3 (0.0%) 60,962 (51.5%) CEZ (N=143,723) I:42 (0.0%) 143,635 (99.9%) R:46 (0.0%) CVA/AMPC (N=19,281) R:14 (0.1%) 19,265 (99.9%) 判定不能 :2
More informationPCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC= Piperacillin
Key words : Clinical isolates, Antibacterial susceptibility, Scale of hospital PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC=
More informationCHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 33( 33 ) 2002 JA * 1 * 2 2003 12 15 * 1) * 2) 34( 34 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 1982 7 2002 (2002.4 2003.3) 1 174 131 (75.3%) 334 171 163 Staphylococcus
More information02-(a)-Łi’ì™·Łv-4.11
THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 105( 13 ) 2001 1) 2) 3) JA 2 7 1) 2) 3) 106( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. 1982 7 2001 (2001.4 2002.3) 1 221 175 (79.2%) 420 186 234 Staphylococcus
More information2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 Feb Neisseria gonorrhoeae ceftriaxone CTRX % 2010 CTRX 20 FQ staphylococci, E. faecium, N.
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 1 1 2013 69 11,762 2015 11 16 1994 2013 69 19 11,762 FQ 33 Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae
More information70( 70 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Meropenem 2002 * * * * * * * * * * * * * * * * * * * * * * NTT Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 71( 71 ) * * * * 2003 12 22 Meropenem
More informationTable 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
More informationCHEMOTHERAPY OCT. 1994 Tazobactam Piperacillin Fig. I. Chemical structures of tazobactam and piperacillin. Table 1. Media used for preculture and MIC determination BHIB: Brain heart infusion broth (Difco),
More informationCHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
More information(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia
Key words: Blood culture, Trend of bacterial isolation, Increasing of staphylococcus, Use of new cephems (ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor
More informationCHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle
VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69
More informationTable 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
More information日本化学療法学会雑誌第51巻第4号
000 000 0 000 0 Methicillin resistant Staphylococcus aureusmrsa.methicillin resistant S. epidermidismrse.0 MRSA MRSE arbekacinabkquinupristindalfopristinqprdpr vancomycin MIC0. ml Streptococcus pneumoniae
More informationVOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia
ceftazidime, cefpirome, cefepime, cefoperazone/sulbactam (2: 1), imipenem Staphylococcus aureus oxacillin coagulase negative staphylococci Escherichia coli piperacillin Klebsiellac spp. Citrobacter Pseudomonas
More informationCHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc
APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus
More information1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus
More informationStaphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
More informationCHEMO THE RAPY OCT. 1994
bilis (0.78), Proteus vulgaris (1.56), Enterococcus faecalis (3.13), Staphylococcus epidermidis (6.25), Klebsiella pneumoniae (6.25), Morganella morganii (6.25), Escherichia coli (12.5), Providencia rettgeri
More informationTable 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,
More informationTable 1. Antimicrobial drugs using for MIC
Table 1. Antimicrobial drugs using for MIC Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive
More informationepidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
More informationCHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str
cefaclor(ccl),cefuroxime(cxm),cefixime (CFIX),cefteram(CFTM),cefdinir(CFDN) pneumoniae,streptococcus pyogenes Moraxella catarrhalis,haemophilus influenzae,escherichia coli, Klebsiella pneumoniae,proteus
More informationTable 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium
THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterobacter spp., Serratia spp., Burkholderia cepacia, Flavobacterium spp., Alcaligenes spp. THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 243 ( 37 ) 2007 12 2008 5 19 863 methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof
242 ( 36 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 prulifloxacin * ** ** CMC * ** 2010 2 22 Prulifloxacin ulifloxacin (UFX) 3 1 2003 12 2004 5 19 534 2 2005 12 2006 5 19 805 3 THE JAPANESE JOURNAL OF
More informationVOL. 43 NO. 4
VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics
More informationR01
1. 集計対象医療機関数 (1,792 医療機関 ) 13.2% (7 医療機関 ) 900 床以上 N=53 86.8% (46 医療機関 ) 19.2% (70 医療機関 ) 500 899 床 N=365 80.8% (295 医療機関 ) JANIS 参加 * 200 499 床 N=2,231 43.4% (968 医療機関 ) 56.6% (1,263 医療機関 ) JANIS 参加 200
More informationFig.1 Chemical structure of BAY o 9867
Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985
More informationpneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.
pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P. aeruginosa 30, P. maltophilia pyogenes 32, Escherichia
More informationCHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
More informationTable 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
More informationDec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 45 ) ) 1) 2) 2) 3) 4) 4,5) 6) 6) 7) 8) 8) 9) 10) 11) 11) 12) 13) 13) 14) 14) 15) 15) 1
Dec. 2010 THE JAPANESE JOURNAL OF ANTIBIOTICS 63 46 431 ( 45 ) 2006 1) 1) 2) 2) 3) 4) 4,5) 6) 6) 7) 8) 8) 9) 10) 11) 11) 12) 13) 13) 14) 14) 15) 15) 16) 16) 17) 17) 1) 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10)
More informationVOL.30 NO.12 CHEMOTHERAPY Fig. 1 Effect of temperature on the growth curve of A. calcoaceticus A. calcoaceticits Ac 54 A. calcoacetictts Ac 164 Fig. 2 Effect of medium ph on the growth curve of A. calcoaceticus
More informationOct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz
Oct. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 5 327 27 2013 2014 2016 7 5 2013 2014 Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, tazobactam/piperacillin TAZ/PIPC, ceftazidime CAZ, cefepime
More information172( 38 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 2 Apr. 2002 1 19 6 2002 5 8 4 254 254 (PBP) 90 83 65 142 PBP pbp1a, pbp2x, pbp2b 121 (49%), pbp1a, pbp2x 30 (12%), pbp2x, pbp2b 16 (6%), pbp2x 61 (24%),
More informationFeb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 11( 11 ) 2003 12 17 (MRSA) penicillin-resistant Streptococcus pneumoniae (PRSP) 3 I. 12( 12 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 3 1997 1) (1985)
More informationDIC vegetation 1 nonbacterial thrombogenic e
2001 2002 Guidelines for the Prevention and Treatment of Infective Endocarditis (JCS 2003) h 1 1 2 3 4 5 6 7 8 9 2 1 2 3 1 2 3 4 1 2 5 1 2 1 G Streptococcus viridans Streptococcus bovis 2 G Streptococcus
More informationCHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);
VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical
More informationCHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative
More informationApr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 13 ) 2008 NTT
Apr. 2010 THE JAPANESE JOURNAL OF ANTIBIOTICS 63 12 105 ( 13 ) 2008 NTT 106 ( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr. 2010 JA 2010 1 27 1982 7 2008 2008 4 2009 3 1 215 173 (80.5%) 694 18 357
More information公開情報 2016 年 1 月 ~12 月年報 ( 全集計対象医療機関 ) 院内感染対策サーベイランス検査部門 Citrobacter koseri Proteus mirabilis Proteus vulgaris Serratia marcescens Pseudomonas aerugino
公開情報 2016 年 1 月 ~12 月年報 ( 全集計対象医療機関 ) 院内感染対策サーベイランス検査部門 検査部門におけるサーベイランスの概要と目的 本サーベイランスの目的は 細菌検査により検出される主要な細菌の分離頻度とその抗菌薬感受性を継続的に収集 解析し 医療機関における主要な細菌ならびに薬剤耐性菌の分離状況を明らかにすることである サーベイランスの対象となる主要菌ならびに薬剤耐性菌の分離率は
More informationTable 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
More informationAug THE JAPANESE JOURNAL OF ANTIBIOTICS (9) 2007 NTT JA
Aug. 2009 THE JAPANESE JOURNAL OF ANTIBIOTICS 62 44 277 (9) 2007 NTT JA 278 (10) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug. 2009 2009 4 10 1982 7 2007 2007 4 2008 3 1 229 181 (79.0%) 683 24 395 288
More informationCHEMOTHERAPY NOV Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aur
CHEMOTHERAPY NOV. 1985 Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aureus Streptococcus pyogenes Escherichia coli Klebsiella
More informationClostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS ( 79)
346 ( 78) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 2007 72 12,919 NTT THE JAPANESE JOURNAL OF ANTIBIOTICS 62 44 347 ( 79) 348 ( 80) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 THE JAPANESE JOURNAL OF
More informationCHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali
CHEMOTHERAPY DEC. 1988 (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis Pseudomonas aeruginosa, Serratia ma- Fig. 1. Chemical
More informationVOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
More informationCHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz
VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine
More informationKey words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
More informationCHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
More information49619, H. influenzae ATCC49247, C. jejuni ATCC 33252, C. fetus ATCC15296, B. fragilis ATCC 25285, C. soldellii ATCC9714, P. rnagnus ATCC lin (ABPC), e
Key words: MIC, agar dilution method, fastidious bacteria, Etes(R) 49619, H. influenzae ATCC49247, C. jejuni ATCC 33252, C. fetus ATCC15296, B. fragilis ATCC 25285, C. soldellii ATCC9714, P. rnagnus ATCC
More informationCHEMOTHERAPY
VOL.40 S-1 coagulase negative Staphylococcus sp, methicillin- resistant Staphylococcus aureus (MRSA), Enterococcus faecalis, Escherichia coli, Citrobacter freundii, Klebsiella pneumoniae, Enterobacter
More informationVOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC
VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC, E. coli NIHJ JC-2 pneumoniae E. coli 106, K. pneumoniae
More informationスライド タイトルなし
第 4 回ひびき臨床微生物シンポジュウム June 24,27, 港ハウス 感受性検査を読む ( 同定検査結果確認やスクリーニング検査と捉えて ) ( 株 ) キューリン小林とも子 キューリン微生物検査課 塗抹鏡検グラム染色 分離培養検査血液 BTB, エッグーヨーク 報告書作成結果承認 同定検査 VITEK TSI,LIM クリスタル NF 薬剤感受性検査 MIC2 ディスク法 薬剤感受性結果 (
More information988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
More information日本化学療法学会雑誌第58巻第4号
Escherichia coli Enterococcus faecalisstreptococcus agalactiae Klebsiella pneumoniae Staphylococcus epidermidis E. colie. faecalispseudomonas aeruginosa K. pneumoniae S. agalactiae E. coli E. coli μ p
More informationVOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT
More informationFig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella
More informationCHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk
VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp, CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus,
More information1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
More informationVOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega
1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon
June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 189 49 1 : 14 1 2 2 3 1 2 3 2015 4 3 1 : 14 CVA/AMPC 1 : 14 27 CVA/AMPC 1 : 14 88.5% Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
More informationTable 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
More information日本化学療法学会雑誌第53巻第S-1号
Doripenem in vitro Doripenem in vitro 7 7 3 DRPM in vitro DRPM 00 DRPM Staphylococcus Streptococcus µ gml MIC90 Moraxella catarrhalishaemophilus influenzae µ gml MIC90 imipenem IPM panipenem meropenemmepm
More informationNationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Assoc
J Infect Chemother (2012) 18:609 620 DOI 10.1007/s10156-012-0434-3 SURVEILLANCE Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of
More informationCHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac
CHEMOTHERAPY DEC. 1988 phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepacia 1 Bacteroides bivius Propionibacterium granulosum
More information366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486
More informationFig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic
More informationVOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum
VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae methicillin-resistant Staphylococcus
More informationCHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
More informationVOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St
CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table
More informationスライド タイトルなし
広域 β-lactamase のスクリーニング法と確認試験 産業医科大学村谷哲郎 β ラクタム系 H C H 2 C O CH 2 O C β-lactam 環 H S O H H S CH 3 CH 3 COOH Ampicillin ペニシリン系 Cefazolin セフェム系 Imipenem H 3 C カルバペネム系 O OH C H O CH 2 S S CH 3 COOH SCH 2
More informationMicrosoft PowerPoint .片山(HP用修正).pptx
平成 29 年度 第 1 回三重県感染対策 援ネットワーク研修会 2017/07/09 ( 臨床第 2 講義室 ) 講演 2 アンチバイオグラムの活 アンチバイオグラム作り 使い 独 政法 地域医療機能推進機構 四 市 津医療センター 薬剤科 副薬剤科 歳也 Japan Community Health care Organization (JCHO) Yokkaichi Hazu Medical
More information日本化学療法学会雑誌第53巻第S-3号
moxifloxacin in vitro moxifloxacin in vitro 17 9 6 17 11 21 moxifloxacinmflx in vitro cefdinir CFDNclavulanic acidamoxicillincvaampcclarithromycincamclindamycincldm levofloxacinlvfx 1MFLX Clostridium clostridiiformeclostridium
More informationTable 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
More informationb) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates
More information* Antibiotic resistance: PCG, penicillinase positive; DMPPC, methicillin and other Ĉ-lactams; EM, macrolides and lincomycins; KM, producing a 3'-phosphotransferase; GM, producing a dual enzyme having
More informationKey words: Antibiotics, Intestinal bacterial flora, Germfree mouse
Key words: Antibiotics, Intestinal bacterial flora, Germfree mouse Table 1 Susceptibility to various antibiotics Antibiotics Abbreviations ABPC: GM: CET: CEZ: CMZ: LMOX: CMX: Bacteriae used Ampicillin
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 NTT
June 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 181 27 201072 12,866 JA 182 28 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 NTT June 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 183 29 2012 3
More informationFig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
More informationShigella flexneri 2a, Shigella flexneri 3a, Shigella sonnei, Salmonella, Salmonella arizonae, Citorobacter freundii, Enterobacter aerogenes, Enterobac
Key words: Edwardsiella tarda from Healthy Persons, H2S firoducinr. Escherichia coli Shigella flexneri 2a, Shigella flexneri 3a, Shigella sonnei, Salmonella, Salmonella arizonae, Citorobacter freundii,
More informationCHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
More informationFeb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 53 53 Tebipenem pivoxil 1 1, 3 2 2 1 1 Meiji Seika 2 Meiji Seika G 3 Meiji Seika 2015 12 15 Tebipenem pivoxil 10% 2010 4 2013 3 3,547 3,540 3,540 3,331
More informationCHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
More information01-a-”Oı€™JŠY-4.02
Apr. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 105( 1 ) Fosfomycin b- 2004 11 24 fosfomycin (FOM) FOM b- (cefazolin (CEZ), cefotiam (CTM), cefmetazole (CMZ) piperacillin (PIPC)) b - AmpC b- FOM glucose-6-phosphate
More informationヒビスコール液A カタログ
1 2 3 2002 10 Centers for Disease Control and Prevention CDC A 1. 2. 0.2% 3. 1 A 2 3 4 5 6 7 1 1 1. 2. 3. 2 1. 1 0.2% 10 Pseudomonas aeruginosa ATCC 27853 20 20 Proteus vulgaris ATCC 13315 30 20 Escherichia
More information「薬剤耐性菌判定基準」 改定内容
Ver.3.1 Ver.3.2 改訂内容 (2019 年 1 月 ) 改訂対象改訂前改訂後 メチシリン耐性黄色ブドウ球菌 (MRSA) ペニシリン耐性肺炎球菌 (PRSP) 多剤耐性緑膿菌 (MDRP) 多剤耐性アシネトバクター属 (MDRA) 概要 MPIPC が R の Staphylococcus aureus ( または CFX がディスク拡散法で R ) または選択培地で MRSA と確認された菌微量液体希釈法の基準
More informationMIC MIC...
50 mg 10% 2.7.36 2.7.36 2.7.36... 1 1.6... 1 2.6... 3 3.6... 5 3.16... 5 3.26... 12 3.36... 16 4.6... 17 5.6... 19 6.6... 20 2.7.3.3.16-1 MIC... 9 2.7.3.3.16-2 MIC... 10 2.7.3.3.16-3 MIC E. coli... 11
More informationStaphylococcus aureus (MSSA) 薬剤感受性情報 2017 年 05 月 1 薬剤感受性結果 系統 薬剤記号 商品名 株数 S( 感性 ) % I( 中間 ) R( 耐性 ) CEZ セファメシ ン CTM ハ ンスホ リン セフェ
Staphylococcus aureus (MSSA) 薬剤感受性情報 17 年 5 月 セファメシ ン 83 CTM ハ ンスホ リン 83 セフェム オキサセフェム系注射薬 ロセフィン 182 99 1 ファーストシン 48 セフメタソ ン 83 フルマリン 48 セフソ ン 147 フロモックス 182 94 4 2 メイアクト 182 98 2 チエナム 83 オラヘ ネム 147 ファロム
More informationTable 1. MICs of fosfomycin and other antibiotics determined by agar dilution method against Pseudomonas aeruginosa FOM: fosfomycin, PIPC: piperacilli
Key words: Pseudomonas aeruginosa, fosfomycin, ofloxacin, Table 1. MICs of fosfomycin and other antibiotics determined by agar dilution method against Pseudomonas aeruginosa FOM: fosfomycin, PIPC: piperacillin,
More informationcoccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin
More informationCHEMOTHERAPY Table 1 Clinical effect of Sultamicillin
CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.
More information概要 (2004 年分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 ( ) 内は施設数 2002 年 2003 年 2004
More information